지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.3
- 수록면
- 161 - 169 (9page)
- DOI
- 10.4093/dmj.2023.0240
이용수
초록· 키워드
오류제보하기
Metabolic dysfunction-associated steatotic (fatty) liver disease (MASLD), previously termed non-alcoholic fatty liver disease, is a worldwide epidemic that can lead to hepatic inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The disease is typically a component of the metabolic syndrome that accompanies obesity, and is often overlooked because the liver manifestations are clinically silent until late-stage disease is present (i.e., cirrhosis). Moreover, Asian populations, including Koreans, have a higher fraction of patients who are lean, yet their illness has the same prognosis or worse than those who are obese. Nonetheless, ongoing injury can lead to hepatic inflammation and ballooning of hepatocytes as classic features. Over time, fibrosis develops following activation of hepatic stellate cells, the liver’s main fibrogenic cell type. The disease is usually more advanced in patients with type 2 diabetes mellitus, indicating that all diabetic patients should be screened for liver disease. Although there has been substantial progress in clarifying pathways of injury and fibrosis, there no approved therapies yet, but current research seeks to uncover the pathways driving hepatic inflammation and fibrosis, in hopes of identifying new therapeutic targets. Emerging molecular methods, especially single cell sequencing technologies, are revolutionizing our ability to clarify mechanisms underlying MASLD-associated fibrosis and HCC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Immunopathogenesis of liver fibrosis in steatotic liver disease
Clinical and Molecular Hepatology
2024 .04
-
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Clinical and Molecular Hepatology
2021 .01
-
Non-alcoholic Fatty Liver Disease (NAFLD) and Significant Hepatic Fibrosis Defined by Non-invasive Assessment in Patients with Type 2 Diabetes
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction- associated fatty liver disease: Directed acyclic graphs
Clinical and Molecular Hepatology
2022 .04
-
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2022 .07
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Clinical and Molecular Hepatology
2023 .01
-
Clinical application of liver stiffness measurement for assessing the risk of hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
-
Autophagy regulatory molecules in hepatic stellate cells for liver fibrosis
한국실험동물학회 학술발표대회 논문집
2018 .07
-
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Gut and Liver
2024 .03
-
Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease
Gut and Liver
2017 .01
-
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Endocrinology and Metabolism
2022 .06
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
비침습적 간섬유화 검사의 적용
대한내과학회지
2023 .04
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Clinical and Molecular Hepatology
2023 .02
-
Current role of transient elastography in the management of chronic hepatitis B patients
ULTRASONOGRAPHY
2017 .01
-
Evaluation of disease severity using multimodal MR imaging in hepatic fibrosis animal model
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Gut and Liver
2021 .01
-
Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
Clinical and Molecular Hepatology
2020 .01
-
Hepatic and Splenic Volumetry Could Be Used as an Imaging Parameter to Evaluate Fibrosis Grades of the Diffuse Liver Disease Including Nonalcoholic Fatty Liver Disease
Gut and Liver
2017 .01
최근 본 자료
댓글(0)
0